On October 22, 1999, the Advisory Committee on Immunization Practices (ACIP) recommended that Rotashield(R) (rhesus rotavirus
vaccine-tetravalent [RRV-TVI), the only U.S-licensed rotavirus vaccine, no longer be used in the United States (MMWR, Vol.
A live, tetravalent (serotypes G1, G2, G3, and G4) rhesus rotavirus vaccine (RRV), RotaShield, was licensed in 1998.
Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children.
Effect of rhesus rotavirus
vaccine on enteric adenovirus-associated diarrhea in children.
In July 1999, CDC recommended that health-care providers and parents postpone use of the rhesus rotavirus
vaccine-tetravalent (RRV-TV) (RotaShield(r) [*], Wyeth Laboratories, Inc., Marietta, Pennsylvania), for infants, at least until November 1999.
A rhesus rotavirus, quadravalent oral vaccine, currently being considered for licensure, may be given concurrently with other routine infant immunizations and has an efficacy rate of 80% against severe disease.
An example would be the rhesus rotavirus (RRV) strain MMU 18006, which is immunogenic when used as a vaccine and is serologically related to one of the four human rotavirus serotypes (Bernstein, Glass, Rodgers, Davidson, & Sack, 1995).